Search Results - "Skaletskaya, Anna"
-
1
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Published in Clinical cancer research (01-09-2014)“…The CD38 cell surface antigen is expressed in diverse hematologic malignancies including multiple myeloma, B-cell non-Hodgkin lymphoma (NHL), B-cell chronic…”
Get full text
Journal Article -
2
Synthesis and Evaluation of Camptothecin Antibody–Drug Conjugates
Published in ACS medicinal chemistry letters (10-10-2019)“…Antibody–drug conjugates (ADCs) that incorporate the exatecan derivative DXd in their payload are showing promising clinical results in solid tumor…”
Get full text
Journal Article -
3
A Cytomegalovirus-Encoded Inhibitor of Apoptosis That Suppresses Caspase-8 Activation
Published in Proceedings of the National Academy of Sciences - PNAS (03-07-2001)“…We have identified a human cytomegalovirus cell-death suppressor, denoted vICA, encoded by the viral UL36 gene. vICA inhibits Fas-mediated apoptosis by binding…”
Get full text
Journal Article -
4
Cytomegalovirus Cell Death Suppressor vMIA Blocks Bax- but Not Bak-Mediated Apoptosis by Binding and Sequestering Bax at Mitochondria
Published in Proceedings of the National Academy of Sciences - PNAS (25-05-2004)“…We report that the cytomegalovirus-encoded cell death suppressor vMIA binds Bax and prevents Bax-mediated mitochondrial membrane permeabilization by…”
Get full text
Journal Article -
5
murine cytomegalovirus cell death suppressor m38.5 binds Bax and blocks Bax-mediated mitochondrial outer membrane permeabilization
Published in Apoptosis (London) (01-09-2008)“…Apoptosis is increasingly implicated as an early line of defense against viral infections. Viruses have devised numerous strategies to delay apoptosis of…”
Get full text
Journal Article -
6
A Cytomegalovirus-Encoded Mitochondria-Localized Inhibitor of Apoptosis Structurally Unrelated to Bcl-2
Published in Proceedings of the National Academy of Sciences - PNAS (26-10-1999)“…Human cytomegalovirus (CMV), a herpesvirus that causes congenital disease and opportunistic infections in immunocompromised individuals, encodes functions that…”
Get full text
Journal Article -
7
Differential function and expression of the viral inhibitor of caspase 8-induced apoptosis (vICA) and the viral mitochondria-localized inhibitor of apoptosis (vMIA) cell death suppressors conserved in primate and rodent cytomegaloviruses
Published in Virology (New York, N.Y.) (25-11-2003)“…Human cytomegalovirus (CMV) genes UL36 and UL37 encode viral inhibitor of caspase-8-induced apoptosis (vICA) and viral mitochondria inhibitor of apoptosis…”
Get full text
Journal Article -
8
An Anti-apoptotic Viral Protein That Recruits Bax to Mitochondria
Published in The Journal of biological chemistry (21-05-2004)“…The viral mitochondria-localized inhibitor of apoptosis (vMIA), encoded by the UL37 gene of human cytomegalovirus, inhibits apoptosis-associated mitochondrial…”
Get full text
Journal Article -
9
The Sequence and Antiapoptotic Functional Domains of the Human Cytomegalovirus UL37 Exon 1 Immediate Early Protein Are Conserved in Multiple Primary Strains
Published in Virology (New York, N.Y.) (05-01-2001)“…The human cytomegalovirus UL37 exon 1 gene encodes the immediate early protein pUL37x1 that has antiapoptotic and regulatory activities. Deletion mutagenesis…”
Get full text
Journal Article -
10
ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
Published in Blood (15-11-2022)Get full text
Journal Article -
11
Abstract 2186: Peptide-cleavable maytansinoid (ADCs) induce high bystander killing leading to improved anti-tumor activity in vivo
Published in Cancer research (Chicago, Ill.) (01-07-2017)“…Abstract Antibodies targeting surface antigens on cancer cells typically have progressively lower access to tumor cells that are further removed from blood…”
Get full text
Journal Article -
12
A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
Published in Molecular cancer therapeutics (01-06-2016)“…A triglycyl peptide linker (CX) was designed for use in antibody -: drug conjugates (ADC), aiming to provide efficient release and lysosomal efflux of…”
Get full text
Journal Article -
13
Abstract 215: Generation of site-specific DARPin® drug conjugates using EGFR as a model system
Published in Cancer research (Chicago, Ill.) (01-07-2019)“…Abstract DARPin® molecules are small engineered proteins, derived from natural ankyrin repeat proteins that are selected to bind to specific targets with high…”
Get full text
Journal Article -
14
Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing
Published in Bioconjugate chemistry (18-11-2015)“…Antibody anilino maytansinoid conjugates (AaMCs) have been prepared in which a maytansinoid bearing an aniline group was linked through the aniline amine to a…”
Get full text
Journal Article -
15
Abstract 71: Bystander activity and in vivo efficacy of a folate receptor α (FRα)-targeting antibody-drug conjugate with a novel peptide linker
Published in Cancer research (Chicago, Ill.) (01-07-2017)“…Abstract Folate receptor α (FRα) is an antigen that is overexpressed on the cell surface of solid tumors including ovarian cancer. The differential expression…”
Get full text
Journal Article -
16
Abstract 2700: ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML
Published in Cancer research (Chicago, Ill.) (04-04-2023)“…Abstract Targeted protein degraders (TPDs) have expanded the breadth of therapeutic options through both their catalytic mechanism of action and ability to…”
Get full text
Journal Article -
17
Abstract 2118: Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader
Published in Cancer research (Chicago, Ill.) (04-04-2023)“…Abstract Breast cancer is the most common invasive cancer in women worldwide and remains a clinical challenge. Addressing the unmet need for better…”
Get full text
Journal Article -
18
Abstract 4436: A novel antibody-enabled dual precision targeted protein stabilization (TPS2) that augments anti-tumor immune response by targeting CBL-B inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1
Published in Cancer research (Chicago, Ill.) (04-04-2023)“…Abstract It is well-established that T cells play a key role in the success of cancer immunotherapies. The goals of T cell-targeting therapies have been to…”
Get full text
Journal Article -
19
Abstract 4513: IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors
Published in Cancer research (Chicago, Ill.) (01-10-2014)“…Abstract EGFR is one of the oncogenic drivers in non-small-cell lung adenocarcinoma (NSCLC AC). EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib,…”
Get full text
Journal Article -
20
Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing
Published in ACS medicinal chemistry letters (10-10-2019)“…A new type of antibody–drug conjugate (ADC) has been prepared that contains a sulfur-bearing maytansinoid attached to an antibody via a highly stable…”
Get full text
Journal Article